EICHORPublic-registry site landscape for NCT03257046, “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease”, a Parkinson Disease study sponsored by Intra-Cellular Therapies, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03257046 (registry record) |
| Study title | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease |
| Official title | A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease |
| Sponsor | Intra-Cellular Therapies, Inc. |
| Condition(s) | Parkinson Disease |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 2 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03257046.
Eichor generates a preliminary site-risk snapshot for NCT03257046 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Parkinson Disease trials
More from Intra-Cellular Therapies, Inc.
← Eichor home · All tracked trials · Parkinson Disease studies · Weekly briefs
